On September 29, 2025, Hangzhou Yaoaccelerated Medical Isotope Technology Co., Ltd. (hereinafter referred to as "Yaoaccelerated"), a hard technology enterprise committed to breaking through the bottleneck of GMP level medical isotope supply, announced the completion of tens of millions of yuan in angel round financing.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Sirop
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-1-218
Apelin-13 CAS 217082-58-1
HS Code: N/A
Molecular formula:C69H111N23O16S
Molecular weight:1550.83
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide Apelin-13 Peptide, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/synthetic-chemical/peptide/apelin-13-peptide.html
This round of financing is jointly participated by Zhejiang University Innovation Institute, Bangming Capital, and industry partner Wuzhou Medical, with Light Source Capital serving as the exclusive financial advisor. The financing funds will mainly be used for expanding the core team, advancing technology research and development, and advancing the commercialization process of key products such as the A-nuclide Ac-225.
Yao Acceleration is committed to breaking through the bottleneck of medical isotope supply, aiming to build a high-performance, high-efficiency, and replicable domestically produced nuclide technology engineering system. The company is building an integrated platform of "high-energy and high flow electron accelerator+high-power target station system+GMP level separation and purification process" around the production technology of medical radioactive isotopes driven by electron accelerators, promoting the large-scale preparation and engineering landing of integrated nuclides in steel and diagnosis and treatment.
The company has built a precision target station, fast heat exchange structure, and short-range efficient cooling path with high-power load capacity based on a self-designed high-power electron linear accelerator system. Combined with multi-stage separation and purification processes, it achieves stable production and strict quality control of key cores such as Ac-225, Cu-67, Sc-47, Mo-99, etc. The entire system supports rapid replacement of targets, remote maintenance, and modular expansion capabilities, suitable for continuous operation scenarios, laying a solid hardware foundation for the large-scale production of nuclides such as Ac-225.
The Yao Acceleration R&D team has gathered experts in accelerator physics, electric vacuum, and nuclear chemical separation from institutions such as the Chinese Academy of Sciences, University of Science and Technology of China, and Harbin Institute of Technology. They possess expertise in accelerator design and manufacturing, nuclear reaction path optimization, and nuclear chemistry separation
The full chain technical capability for scaling up and industrialization of the separation process technology.
After the completion of this round of financing, Yao Acceleration will further accelerate the company's production line construction and technological iteration, promote the commercial production and delivery of core nuclides such as Ac-225, and help China's nuclear medicine diagnosis and treatment industry achieve high-quality independent development.
Baili Tianheng's first antibody radionuclide conjugate drug has been approved for clinical trial approval
On September 29, 2025, according to the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration, the clinical trial application for Baili Tianheng's first antibody radionuclide conjugate drug (ARC) lutetium [177Lu] - BL-ARC001 injection was granted implied permission, intended for use in locally advanced or metastatic solid tumors, including but not limited to those that have failed standard treatment or cannot receive standard treatment.
Lutetium [177Lu] - BL-ARC001 is the first class innovative drug in the field of antibody radiolabeled conjugate drugs developed by Baili Tianheng based on the company's independently developed HIRE-ARC platform. It is also the company's potential first in class ARC drug with completely independent intellectual property rights.
Lutetium [177Lu] - BL-ARC001, through antibody mediated precise targeted delivery technology and strong tumor killing ability of radioactive isotopes, has stronger target specificity, higher tumor enrichment, and is expected to exhibit better anti drug resistance compared to traditional radioactive isotope coupled drugs.
This clinical trial application for implied permission marks an important step for the company in the field of nuclear drug research and development.
Baili Tianheng is a company that focuses on the forefront of global biopharmaceutical fields, focusing on solving unmet clinical needs. It has global leading innovative research and development capabilities, global clinical development, and large-scale production and supply capabilities in the field of tumor macromolecular therapy (ADC/GNC/ARC), and has gradually developed into a comprehensive biopharmaceutical enterprise with global commercialization capabilities.
